Clinical efficiency and tolerability of artrofoon in patients with rheumatoid arthritis associated with osteopenic syndrome.
Clinical, laboratory, densitometric, and prognostic parameters were evaluated in 50 patients with rheumatoid arthritis complicated with osteopenic syndrome, 30 of these received artofoon for 12 months in addition to basis therapy. Antiinflammatory and analgesic effects of artrofoon were demonstrated and the possibility of using this preparation in pharmacotherapy of rheumatoid arthritis associated with osteopenic syndrome was proven.